|
|
T2 Biosystems Postpones Reporting of First Quarter 2023 Financial Results
|
|
|
T2 Biosystems to Report First Quarter 2023 Financial Results on May 15, 2023
|
|
|
T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference
|
|
|
T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices
|
|
|
T2 Biosystems Affirms Plans to Add Candida Auris Detection to the FDA-Cleared T2Candida Panel
|
|
|
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
|
|
|
T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
|
|
|
T2 Biosystems Announces Pricing of $12 Million Public Offering
|
|
|
T2 Biosystems Announces Proposed Public Offering
|
|
|
T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel
|
